Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS [NYSE]
Novartis AG
Index- P/E18.59 EPS (ttm)4.34 Insider Own9.30% Shs Outstand2.24B Perf Week-1.55%
Market Cap196.34B Forward P/E12.09 EPS next Y6.67 Insider Trans0.00% Shs Float2.10B Perf Month-2.45%
Income9.81B PEG2.65 EPS next Q1.61 Inst Own10.00% Short Float0.28% Perf Quarter-12.30%
Sales52.38B P/S3.75 EPS this Y14.20% Inst Trans-0.26% Short Ratio2.78 Perf Half Y-8.69%
Book/sh25.38 P/B3.18 EPS next Y5.75% ROA7.90% Target Price104.00 Perf Year-9.51%
Cash/sh3.35 P/C24.05 EPS next 5Y7.02% ROE18.00% 52W Range81.01 - 98.52 Perf YTD-14.54%
Dividend3.20 P/FCF30.75 EPS past 5Y4.10% ROI8.80% 52W High-18.09% Beta0.59
Dividend %3.97% Quick Ratio0.60 Sales past 5Y-0.20% Gross Margin70.60% 52W Low-0.38% ATR0.98
Employees108000 Current Ratio0.90 Sales Q/Q6.60% Oper. Margin22.50% RSI (14)36.27 Volatility0.94% 0.81%
OptionableYes Debt/Eq0.60 EPS Q/Q45.60% Profit Margin18.70% Rel Volume0.81 Prev Close81.91
ShortableYes LT Debt/Eq0.44 EarningsOct 26 BMO Payout70.70% Avg Volume2.13M Price80.70
Recom2.00 SMA20-2.49% SMA50-2.64% SMA200-8.03% Volume1,719,042 Change-1.48%
Sep-20-21Downgrade Deutsche Bank Hold → Sell
Mar-22-21Initiated Bernstein Mkt Perform
Mar-10-21Downgrade Argus Buy → Hold
Feb-01-21Downgrade Cowen Outperform → Market Perform $110 → $105
Jan-15-21Initiated Deutsche Bank Buy
Sep-29-20Initiated Berenberg Buy
Sep-10-20Upgrade UBS Neutral → Buy
Sep-01-20Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-15-20Upgrade Citigroup Neutral → Buy
Mar-10-20Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20Downgrade Guggenheim Buy → Neutral
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Nov-26-21 05:18AM  
Nov-25-21 05:55AM  
Nov-23-21 11:52AM  
06:23AM  
Nov-21-21 11:00AM  
Nov-19-21 11:16AM  
10:45AM  
Nov-18-21 02:23PM  
11:54AM  
Nov-16-21 07:04AM  
07:00AM  
05:51AM  
Nov-15-21 01:26PM  
Nov-09-21 11:06PM  
01:14PM  
Nov-08-21 12:00PM  
Nov-06-21 05:00AM  
Nov-05-21 08:40AM  
05:08AM  
03:42AM  
03:42AM  
03:02AM  
Nov-04-21 01:45PM  
10:00AM  
08:29AM  
08:00AM  
07:37AM  
07:32AM  
06:35AM  
05:39AM  
05:32AM  
05:01AM  
02:32AM  
02:16AM  
02:00AM  
Nov-03-21 11:11PM  
Nov-02-21 06:03PM  
07:39AM  
Oct-29-21 03:46PM  
10:41AM  
10:36AM  
Oct-28-21 10:33AM  
Oct-27-21 08:37AM  
Oct-26-21 04:11PM  
02:00PM  
09:55AM  
08:30AM  
07:02AM  
06:34AM  
04:42AM  
01:26AM  
01:00AM  
Oct-25-21 09:44AM  
01:15AM  
Oct-22-21 11:22AM  
09:24AM  
08:38AM  
Oct-21-21 07:02AM  
Oct-19-21 01:15AM  
Oct-14-21 07:50AM  
06:30AM  
Oct-13-21 10:52AM  
Oct-12-21 09:14AM  
Oct-11-21 03:15AM  
Oct-08-21 07:34AM  
Oct-01-21 01:58PM  
11:52AM  
Sep-30-21 01:15AM  
Sep-29-21 02:02PM  
09:28AM  
06:55AM  
Sep-24-21 08:27AM  
Sep-22-21 07:34AM  
Sep-21-21 01:23PM  
09:46AM  
07:07AM  
01:36AM  
Sep-20-21 10:03PM  
12:40PM  
Sep-19-21 07:35AM  
07:30AM  
Sep-17-21 07:30AM  
06:51AM  
Sep-16-21 06:05PM  
11:43AM  
11:02AM  
Sep-13-21 11:35AM  
Sep-08-21 07:01PM  
07:30AM  
Sep-07-21 01:49PM  
Sep-01-21 06:23AM  
Aug-31-21 07:01PM  
07:01PM  
Aug-30-21 01:15AM  
Aug-25-21 03:18PM  
Aug-24-21 11:57AM  
01:15AM  
Aug-17-21 06:17AM  
Aug-04-21 11:58AM  
09:34AM  
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.